NCT07288229Not yet recruiting
The Benefits of Wearable AI in Post-Discharge Management of AMI Patients
The Benefits of Wearable Device-Based Artificial Intelligence in Post-Discharge Management of Patients With Acute Myocardial Infarction
Source: ClinicalTrials.gov · Last updated 17 Dec 2025
Brief summary (registry, in English)
Myocardial infarction (MI) remains a major threat to human health. Although interventional treatment techniques have advanced rapidly, many patients still experience major adverse cardiovascular events (MACE) and require hospital readmission after discharge. Artificial intelligence (AI) based on wearable device data has shown great potential in the diagnosis and management of cardiovascular diseases. This study aims to explore the clinical value of wearable device-based data analysis and AI-driven risk stratification models in post-discharge management of acute myocardial infarction (AMI) patients.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 14 Nov 2025
- Start date
- 30 Dec 2025
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- RenJi Hospital
- Diseases
- Heart failure
- NCT number
- NCT07288229
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 30 Dec 2025 to the primary completion date, 30 Jun 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Planned staged or elective PCI or any coronary revascularization scheduled within 3 months after discharge.
- Unable to tolerate or contraindicated for wearing metal or electronic monitoring devices.
- Pregnant or breastfeeding women.
- Residence in an area without stable network connectivity or inability to use a smartphone for data upload and communication.
- Severe comorbidities that limit 3-month survival or follow-up.
Who the study is looking for
- Adults aged 18 to 75 years.
- Confirmed diagnosis of acute myocardial infarction (AMI), including both ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI).
- Underwent successful percutaneous coronary intervention (PCI) during index hospitalization.
- Hemodynamically stable at the time of hospital discharge.
- Willing and able to wear a smartwatch continuously for the study period.
- Compatible with the data collection application and have stable internet access.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.